TAS 8274

Drug Profile

TAS 8274

Alternative Names: TAS8274

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Immunotherapies
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 11 Nov 2016 Preclinical trials in Rheumatic disorders in Japan (PO)
  • 11 Nov 2016 Taiho Pharmaceuticals plans a phase I trial for Rheumatic Arthritis
  • 11 Nov 2016 Pharmacodynamics data from preclinical studies Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top